Compare Ascendis Pharma A/S (ASND) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Phillips 66 — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Phillips 66 trades at $194.3 (market cap $75.52B). The key difference: Phillips 66 is far larger — about 4.3× Ascendis Pharma A/S's market cap, and Phillips 66 pays a 2.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PSX | |
|---|---|---|
Market Cap | $17.74B | $75.52B |
Sector | Health | Energy |
52-Week High | $277.18 | $189.82 |
52-Week Low | $163.32 | $118.37 |
Enterprise Value | $18.11B | $97.49B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Phillips 66 (PSX) trades at $188.36, down 0.77% on the day, with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 18.6 and P/S of 0.57, while recent quarterly earnings have consistently beaten expectations. The company maintains a 14.75% ROE and recently declared a $1.27 quarterly dividend, reflecting management's confidence in cash flow stability.
PSX presents a compelling value opportunity with upside to the $196.57 consensus price target, supported by 57% analyst buy ratings. Key risks include refining margin volatility from Middle East disruptions and declining revenue trends from $170B in 2022 to $132.4B in 2025. The stock's technical overbought condition near resistance at $191 warrants caution despite positive momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
